Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000266 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000266 C4901309!4901309!26859478     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2016 ; 28 (3): 197-203 Nephropedia Template TP {{tp|p=26859478|t=2016. Anti-inflammatory panacea? The Expanding Therapeutics of IL-1 Blockade |pdf=|usr=}}{{26859478}} gab.com Text Anti-inflammatory panacea The Expanding Therapeutics of IL-1 Blockade JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26859478 #FOAvip Purpose of review: Blockade of IL-1 signaling is one of the oldest biologic therapies, yet the use of these agents is on the rise as the role of IL-1 activation is being recognized in a wide spectrum of inflammatory disorders. This review will cover established and emerging uses of IL-1 antagonism in rheumatic diseases. Recent findings: Expanding off-label indications for IL-1 blockade include neutrophil-dominant skin diseases including pyoderma gangrenosum, hidradenitis supperativa, and pustular psoriasis. There is also increasing evidence for the use of IL-1 blockade in heart failure associated with rheumatic diseases. Somatic mosaicism in NLRP3 may explain the onset of later-in-life presentations of periodic fevers which are responsive to IL-1 blockade. Of importance, clinical response to anti-IL-1 therapy does not always denote protection from autoinflammatory disease complications such as macrophage activation syndrome or amyloidosis. Summary: Indications for IL-1 blocking therapies will likely continue to broaden, but given the rarity of many rheumatic diseases which respond to such treatment, rigorous, large clinical trials for each indication are unlikely to occur. Thus, recommended use of these medications will often fall to the discretion of the astute physician. However, medication cost and hurdles of insurance approval, rather than drug efficacy, may be the primary limitation for more widespread use. Twit Text FOAVip Anti-inflammatory panacea The Expanding Therapeutics of IL-1 Blockade ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26859478 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26859478 #FOAvip English Wikipedia <ref>{{Cite pmid|26859478}}</ref> Anti-inflammatory panacea? The Expanding Therapeutics of IL-1 Blockade #MMPMID26859478 Kahlenberg JM Curr Opin Rheumatol 2016[May]; 28 (3): 197-203 PMID26859478show ga Purpose of review: Blockade of IL-1 signaling is one of the oldest biologic therapies, yet the use of these agents is on the rise as the role of IL-1 activation is being recognized in a wide spectrum of inflammatory disorders. This review will cover established and emerging uses of IL-1 antagonism in rheumatic diseases. Recent findings: Expanding off-label indications for IL-1 blockade include neutrophil-dominant skin diseases including pyoderma gangrenosum, hidradenitis supperativa, and pustular psoriasis. There is also increasing evidence for the use of IL-1 blockade in heart failure associated with rheumatic diseases. Somatic mosaicism in NLRP3 may explain the onset of later-in-life presentations of periodic fevers which are responsive to IL-1 blockade. Of importance, clinical response to anti-IL-1 therapy does not always denote protection from autoinflammatory disease complications such as macrophage activation syndrome or amyloidosis. Summary: Indications for IL-1 blocking therapies will likely continue to broaden, but given the rarity of many rheumatic diseases which respond to such treatment, rigorous, large clinical trials for each indication are unlikely to occur. Thus, recommended use of these medications will often fall to the discretion of the astute physician. However, medication cost and hurdles of insurance approval, rather than drug efficacy, may be the primary limitation for more widespread use. äAnti-inflammatory panacea? The Expanding Therapeutics of IL-1 Blockade(epmc).pdf DeepDyve Pubget Overpricing